Page 3 - Astrazeneca Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi

Amgen incAstrazeneca plcBoxed warningBkemv risk evaluationStock market gameBenzinga proDay trialAmgen secures